id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-299150-1noy0z88	Desai, Aakash	Clinical Trial Endpoints in Severe COVID-19	2020-06-06		.txt	text/plain	686	50	56	However, clinical trials of agents tested for severe COVID19 may not necessarily test for mortality outcomes as the primary endpoint, as was highlighted in the press release of the recent remdesivir trial. Since drugs improving mortality in severe COVID-19 is the most important endpoint to achieve both from clinical and public policy standpoint, we evaluated the type of primary endpoints currently being assessed in randomized controlled trials (RCTs) in severe COVID19. Our analysis found that only 6/19 (30%) ongoing phase III RCT in severe COVID19 have mortality as the standalone primary endpoint or a part of composite endpoint. Given that mortality is as high as 25% in severe COVID19 who need ICU care and average time to death is 3-6 days [2, 3] , the number of mortality events needed and follow-up time do not pose an impediment for analysis of mortality as the primary endpoint.	./cache/cord-299150-1noy0z88.txt	./txt/cord-299150-1noy0z88.txt